VIRUS SAFETY OF HUMAN-IMMUNOGLOBULINS - EFFICIENT INACTIVATION OF HEPATITIS-C AND OTHER HUMAN PATHOGENIC VIRUSES BY THE MANUFACTURING PROCEDURE

被引:36
作者
NOWAK, T
GREGERSEN, JP
KLOCKMANN, U
CUMMINS, LB
HILFENHAUS, J
机构
[1] BEHRINGWERKE AG,SERV,POB 1140,W-3550 MARBURG,GERMANY
[2] WHITE SANDS RES CTR,ALAMOGORDO,NM
关键词
HUMAN IMMUNOGLOBULINS; PASTEURIZATION; FLAVIVIRUS; S-SULFONATION;
D O I
10.1002/jmv.1890360311
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Human immunoglobulins are plasma derivatives with a low risk of transmitting viral infections. To the present, no proven case of human immunoglobulins transmitting human immunodeficiency viruses has been reported. However, there have been a few reports on the transmission of hepatitis C virus by these plasma proteins. To improve further the safety of both 5s iv human immunoglobulins and 7s im immunoglobulins, we introduced a 10-hour heat treatment of the aqueous solutions at 60-degrees-C (i.e., pasteurization) into the manufacturing procedure. This treatment was not added to the manufacturing procedure of 7s iv immunoglobulin that already contained the S-sulfonation as a virus inactivating method. We now report on experimental data that show that the whole manufacturing procedures of the above immunoglobulins inactivate efficiently hepatitis C virus and that the specific virus inactivation methods alone, namely, pasteurization or S-sulfonation, also inactivate completely viruses of the flavivirus family, to which the hepatitis C virus belongs. The inactivation of the Flaviviridae bovine viral diarrhea virus, tick-borne encephalitis virus, and yellow fever virus by pasteurization or S-sulfonation was at least 10(5). The clearance of HCV achieved by the entire manufacturing process of each of these immunoglobulins was also at least 10(5). The experiments therefore show that pasteurization or S-sulfonation provides a high margin of safety to human immunoglobulins regarding the transmission of hepatitis C virus.
引用
收藏
页码:209 / 216
页数:8
相关论文
共 26 条
[11]   TRANSMISSION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 (HIV-1) BY EXPOSURE TO BLOOD - DEFINING THE RISK [J].
KLEIN, RS ;
FRIEDLAND, GH .
ANNALS OF INTERNAL MEDICINE, 1990, 113 (10) :729-730
[12]   AN ASSAY FOR CIRCULATING ANTIBODIES TO A MAJOR ETIOLOGIC VIRUS OF HUMAN NON-A, NON-B-HEPATITIS [J].
KUO, G ;
CHOO, QL ;
ALTER, HJ ;
GITNICK, GL ;
REDEKER, AG ;
PURCELL, RH ;
MIYAMURA, T ;
DIENSTAG, JL ;
ALTER, MJ ;
STEVENS, CE ;
TEGTMEIER, GE ;
BONINO, F ;
COLOMBO, M ;
LEE, WS ;
KUO, C ;
BERGER, K ;
SHUSTER, JR ;
OVERBY, LR ;
BRADLEY, DW ;
HOUGHTON, M .
SCIENCE, 1989, 244 (4902) :362-364
[13]  
LANE RS, 1983, LANCET, V2, P974
[14]  
LEVER AML, 1984, LANCET, V2, P1062
[15]  
Mauler R, 1987, Dev Biol Stand, V67, P337
[16]   TRANSMISSION OF LYMPHOTROPIC RETROVIRUSES (HTLV-I AND LAV/HTLV-III) BY BLOOD-TRANSFUSION AND BLOOD PRODUCTS [J].
MELIEF, CJM ;
GOUDSMIT, J .
VOX SANGUINIS, 1986, 50 (01) :1-11
[17]  
OCHS HD, 1986, LANCET, V1, P322
[18]   NUCLEOTIDE-SEQUENCE AND MUTATION-RATE OF THE H-STRAIN OF HEPATITIS-C VIRUS [J].
OGATA, N ;
ALTER, HJ ;
MILLER, RH ;
PURCELL, RH .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (08) :3392-3396
[19]  
PRINCE AM, 1987, EUR J EPIDEMIOL, V3, P103, DOI 10.1007/BF00239746
[20]  
REED L. J., 1938, AMER JOUR HYG, V27, P493